Stockreport

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; [Read more]